Ontology highlight
ABSTRACT:
SUBMITTER: van Lunzen J
PROVIDER: S-EPMC4804741 | biostudies-literature | 2016 Apr
REPOSITORIES: biostudies-literature
van Lunzen Jan J Pozniak Anton A Gatell Jose M JM Antinori Andrea A Klauck Isabelle I Serrano Oscar O Baakili Adyb A Osiyemi Olayemi O Sevinsky Heather H Girard Pierre-Marie PM
Journal of acquired immune deficiency syndromes (1999) 20160401 5
This open-label, multinational, pilot study randomized (1:2 ratio) adults with HIV-1 RNA <40 copies per milliliter and nucleos(t)ide-related safety/tolerability issues to switch to ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (n = 37) or the nucleos(t)ide reverse transcriptase inhibitor-sparing regimen of ATV/r plus raltegravir (RAL) (n = 72). At 24 weeks, 35/37 (94.6%) and 58/72 (80.6%) of patients, respectively, maintained virological suppression, the p ...[more]